News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
Medical Dialogues27m
Moderna gets USFDA nod for RSV Vaccine mRESVIA in adults aged 18-59 at increased risk for RSV disease
Cambridge: Moderna, Inc. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ...
Asianet Newsable on MSN15m
Moderna’s RSV Vaccine Gets FDA Nod For Younger At-Risk Adults: Retail Stays Guarded Amid RFK Jr’s Immunization Shake-Up
The company plans to make mRESVIA available for both younger and older adults in the U.S. ahead of the 2025-2026 respiratory ...